Copy
EuropaBio's Weekly Newsletter

View it in your browser

EuropaBio Demands the End of Maladministration on GMOs 

The day on which new Commission delays in the handling of authorisation applications for GM food and feed turned again into clear maladministration despite the Ombudsman’s call, EuropaBio urged the President of the EU Commission, Jean-Claude Juncker, to end the Commission’s breach of its obligation. These systemic failures "are driving the innovative businesses of the agricultural biotechnology sector and their vast investments in job creation and R&D outside Europe", says the letter. Read more

EU Should Take a Chance on Innovation

Why is Europe lagging behind in innovation? Simply put, we are obsessed with risk at the expense of ground-breaking technologies. The political assessment of opportunities and risks is imbalanced. This needs to change and regulation should keep up with the ever inventive scientific progress. The solution? A more evidence-based policymaking. Marijn Dekkers, CEO of Bayer, explains how an innovation principle and a precautionary principle would together encourage a better balanced view. Read more

Plain Plastic, Not that Fantastic? 

Plastic has many characteristics that make it commercially successful. However, it also links to environmental and societal challenges. In regards to the evolving circular economy, a few changes need to be made and focus should not just be placed on the so called "technical loop" but also the "carbon loop". The way conventional plastic is made leaves a significant carbon footprint, but bio-based plastics can help reduce it. A kilogramme produced can save around four kilos of CO², so what’s keeping them from being the “now” instead of the “future"? Read more

Agricultural biotech

Not too fond of fish, but still need that omega-3 fix? Rothamsted scientists have received the go-ahead to grow a field trial of GM Camelina oilseed plants fortified with the healthy fatty acid in 2016 and 2017.  Read more

Healthcare biotech

The European Medicines Agency (EMA) has published new guidance on the use of patient-reported outcome (PRO) measures in oncology studies. The new guidance provides recommendations for the incorporation of PROs and health-related quality of life (HRQL) measures in the clinical development of anticancer medicines and advice on appropriate design, conduct, and analysis of PRO studies.
Read more

Industrial biotech

The Bio-Based Industries Joint Undertaking (BBI JU) supports research, demonstrators and flagships bio-refineries with a further €189 million of funding. The 2016 BBI Call targets actors involved in European bio-based industries, and the proposals do not have to be linked to a specific value chain this time. Exciting discoveries for the bioeconomy are in store. Read more
EuropaBio's 20 year anniversary: weekly spotlight on our members
HollandBIO works hard to pave the way for biotech. And is proud that the Dutch biotech sector is booming! As the Dutch biotech industry association, HollandBIO connects, supports and represents medical, agro-food and industrial biotech companies - of all sizes and active in all phases of R&D. The Association helps its members turn science into products, so society can take full advantage of biotechnology, in health, food and sustainability. HollandBIO’s advocacy programs focus on key factors that help Dutch biotech thrive in a competitive global market, and include finance, IP, precision medicines, vaccines and NBTs. Learn more
Key dates to keep in mind
Follow us
Find us on Facebook
Visit our website
Say hello

Our mailing address is:
Avenue de l'Armée 6
B-1040 Brussels

Copyright © 2016 EuropaBio. All rights reserved.
unsubscribe from this list